The use of GPCR structures in drug design.
暂无分享,去创建一个
[1] M. Maccoss,et al. Characterization of a Novel, Non-peptidyl Antagonist of the Human Glucagon Receptor* , 1999, The Journal of Biological Chemistry.
[2] Bartosz Trzaskowski,et al. Predicted 3D structures for adenosine receptors bound to ligands: comparison to the crystal structure. , 2010, Journal of structural biology.
[3] M. Congreve,et al. A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.
[4] Gebhard F. X. Schertler,et al. The structural basis of agonist-induced activation in constitutively active rhodopsin , 2011, Nature.
[5] A. Cashen. Plerixafor hydrochloride: a novel agent for the mobilization of peripheral blood stem cells. , 2009, Drugs of today.
[6] Christoph Seibert,et al. Structural Basis of CXCR4 Sulfotyrosine Recognition by the Chemokine SDF-1/CXCL12 , 2008, Science Signaling.
[7] M. Congreve,et al. Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.
[8] Robert P Bywater,et al. Recognition of privileged structures by G-protein coupled receptors. , 2004, Journal of medicinal chemistry.
[9] A. Hopkins,et al. Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.
[10] M. Sabio,et al. Exploration of structure-based drug design opportunities for mGluRs , 2011, Neuropharmacology.
[11] Gregg Siegal,et al. Fragment screening of stabilized G-protein-coupled receptors using biophysical methods. , 2011, Methods in enzymology.
[12] T. Werge. Identification of an epitope in the substance P receptor important for recognition of the common carboxyl-terminal tachykinin sequence. , 1994, The Journal of biological chemistry.
[13] F. Petitet,et al. Knowledge-based analysis of multi-potent G-protein coupled receptors ligands. , 2010, European journal of medicinal chemistry.
[14] B Clotet,et al. Activity of different bicyclam derivatives against human immunodeficiency virus depends on their interaction with the CXCR4 chemokine receptor. , 1999, Molecular pharmacology.
[15] H. Xu,et al. Molecular recognition of parathyroid hormone by its G protein-coupled receptor , 2008, Proceedings of the National Academy of Sciences.
[16] H. Senderowitz,et al. G protein coupled receptors -in silico drug discovery and design. , 2010, Current topics in medicinal chemistry.
[17] H. Senderowitz,et al. G Protein-Coupled Receptors: target-based in silico screening. , 2009, Current pharmaceutical design.
[18] R. Grisshammer,et al. Purification and characterization of the human adenosine A2a receptor functionally expressed in Escherichia coli , 2002 .
[19] J. Rubin,et al. Chemokine signaling in cancer: one hump or two? , 2009, Seminars in cancer biology.
[20] M. Brann,et al. The Second Intracellular Loop of the m5 Muscarinic Receptor Is the Switch Which Enables G-protein Coupling* , 1998, The Journal of Biological Chemistry.
[21] R. Riek,et al. NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[22] Andreas Plückthun,et al. Directed evolution of a G protein-coupled receptor for expression, stability, and binding selectivity , 2008, Proceedings of the National Academy of Sciences.
[23] J. Holst,et al. Treatment of type 2 diabetes with glucagon‐like peptide‐1 receptor agonists , 2009, International journal of clinical practice.
[24] K. Palczewski,et al. Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.
[25] Claudio N. Cavasotto,et al. Homology modeling in drug discovery: current trends and applications. , 2009, Drug discovery today.
[26] Leonardo Pardo,et al. Structural models of class a G protein-coupled receptors as a tool for drug design: insights on transmembrane bundle plasticity. , 2007, Current topics in medicinal chemistry.
[27] Gianni Chessari,et al. From fragment to clinical candidate--a historical perspective. , 2009, Drug discovery today.
[28] Jonathan A. Javitch,et al. Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist , 2010, Science.
[29] S. Rasmussen,et al. Structure of a nanobody-stabilized active state of the β2 adrenoceptor , 2010, Nature.
[30] Philip J. Reeves,et al. Structure and function in rhodopsin: A tetracycline-inducible system in stable mammalian cell lines for high-level expression of opsin mutants , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[31] Arthur Christopoulos,et al. A Novel Mechanism of G Protein-coupled Receptor Functional Selectivity , 2008, Journal of Biological Chemistry.
[32] J. Ballesteros,et al. [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .
[33] Stefano Costanzi,et al. On the applicability of GPCR homology models to computer-aided drug discovery: a comparison between in silico and crystal structures of the beta2-adrenergic receptor. , 2008, Journal of medicinal chemistry.
[34] Sid Topiol,et al. Use of the X-ray structure of the Beta2-adrenergic receptor for drug discovery. , 2008, Bioorganic & medicinal chemistry letters.
[35] S. Charlton,et al. A common intracellular allosteric binding site for antagonists of the CXCR2 receptor , 2010, British journal of pharmacology.
[36] F. Marshall,et al. RAMPs: accessory proteins for seven transmembrane domain receptors. , 1999, Trends in pharmacological sciences.
[37] Christopher G. Tate,et al. The structural basis for agonist and partial agonist action on a β1-adrenergic receptor , 2010, Nature.
[38] Maria A Miteva,et al. Structure-based virtual ligand screening: recent success stories. , 2009, Combinatorial chemistry & high throughput screening.
[39] F. Blaney,et al. GPCR Homology Model Development and Application , 2010 .
[40] D. Nicholls,et al. Identification of a Putative Intracellular Allosteric Antagonist Binding-Site in the CXC Chemokine Receptors 1 and 2 , 2008, Molecular Pharmacology.
[41] R. Stevens,et al. The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.
[42] S. Hoare,et al. Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. , 2005, Drug discovery today.
[43] H. Kikkawa,et al. The role of the seventh transmembrane region in high affinity binding of a beta 2-selective agonist TA-2005. , 1998, Molecular pharmacology.
[44] W. Goddard,et al. Computational modeling of structure-function of g protein-coupled receptors with applications for drug design. , 2010, Current medicinal chemistry.
[45] R. Stevens,et al. Structure of an Agonist-Bound Human A2A Adenosine Receptor , 2011, Science.
[46] Anat Levit,et al. Homology modeling of G-protein-coupled receptors with X-ray structures on the rise. , 2010, Current opinion in drug discovery & development.
[47] Tom L. Blundell,et al. Keynote review: Structural biology and drug discovery , 2005 .
[48] Andreas Evers,et al. Sequence-derived three-dimensional pharmacophore models for G-protein-coupled receptors and their application in virtual screening. , 2009, Journal of medicinal chemistry.
[49] M. Burghammer,et al. Crystal structure of the human β2 adrenergic G-protein-coupled receptor , 2007, Nature.
[50] W. Weis,et al. Structural insights into G-protein-coupled receptor activation. , 2008, Current opinion in structural biology.
[51] D. Rognan,et al. Selective structure-based virtual screening for full and partial agonists of the beta2 adrenergic receptor. , 2008, Journal of medicinal chemistry.
[52] R. Rudolph,et al. Passing the baton in class B GPCRs: peptide hormone activation via helix induction? , 2009, Trends in biochemical sciences.
[53] Prashant V Desai,et al. Homology modeling of G-protein-coupled receptors and implications in drug design. , 2006, Current medicinal chemistry.
[54] Sid Topiol,et al. X-ray structure breakthroughs in the GPCR transmembrane region. , 2009, Biochemical pharmacology.
[55] B. Kobilka,et al. New G-protein-coupled receptor crystal structures: insights and limitations. , 2008, Trends in pharmacological sciences.
[56] A. IJzerman,et al. The crystallographic structure of the human adenosine A2A receptor in a high-affinity antagonist-bound state: implications for GPCR drug screening and design. , 2010, Current opinion in structural biology.
[57] B. Sykes,et al. Structure‐activity relationships of chemokines , 1995, Journal of leukocyte biology.
[58] Brian K. Shoichet,et al. Structure-Based Discovery of A2A Adenosine Receptor Ligands , 2010, Journal of medicinal chemistry.
[59] Nobuhiro Yamamoto,et al. Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and molecular modeling based on the solved X-ray structure of the beta2-adrenergic receptor: part 6. , 2009, Bioorganic & medicinal chemistry letters.
[60] Stefano Costanzi,et al. Rhodopsin and the others: a historical perspective on structural studies of G protein-coupled receptors. , 2009, Current pharmaceutical design.
[61] Charles L. Brooks,et al. Community-wide assessment of GPCR structure modelling and ligand docking: GPCR Dock 2008 , 2009, Nature Reviews Drug Discovery.
[62] Kenneth Jones,et al. Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds. , 2008, Bioorganic & medicinal chemistry letters.
[63] R. Hodgson,et al. Recent progress in the discovery of adenosine A(2A) receptor antagonists for the treatment of Parkinson's disease. , 2010, Current opinion in drug discovery & development.
[64] A. Gilchrist. GPCR Molecular Pharmacology and Drug Targeting: Shifting Paradigms and New Directions , 2010 .
[65] R. Horuk,et al. I want a new drug: G-protein-coupled receptors in drug development. , 2006, Drug discovery today.
[66] Donald J. Abraham,et al. Burger's medicinal chemistry, drug discovery, and development , 2010 .
[67] Thomas M Frimurer,et al. Ligand binding and micro-switches in 7TM receptor structures. , 2009, Trends in pharmacological sciences.
[68] Patrick Scheerer,et al. Crystal structure of the ligand-free G-protein-coupled receptor opsin , 2008, Nature.
[69] G. Marucci,et al. Adenosine receptor modeling: what does the A2A crystal structure tell us? , 2010, Current topics in medicinal chemistry.
[70] Yoko Shibata,et al. Co-evolving stability and conformational homogeneity of the human adenosine A2a receptor , 2008, Proceedings of the National Academy of Sciences.
[71] Jian Cai,et al. Expression of CB2 cannabinoid receptor in Pichia pastoris. , 2002, Protein expression and purification.
[72] M. Hauser,et al. Unnatural amino acid replacement in a yeast G protein-coupled receptor in its native environment. , 2008, Biochemistry.
[73] R. Duckworth,et al. Expression of a rat neurotensin receptor in Escherichia coli. , 1993, The Biochemical journal.
[74] Stefano Costanzi,et al. A virtual screen for diverse ligands: discovery of selective G protein-coupled receptor antagonists. , 2008, Journal of the American Chemical Society.
[75] Paul E. Kennedy,et al. HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor , 1996, Science.
[76] Frank E. Blaney,et al. 4.26 – Seven Transmembrane G Protein-Coupled Receptors: Insights for Drug Design from Structure and Modeling , 2007 .
[77] Santosh A. Khedkar,et al. Successful applications of computer aided drug discovery: moving drugs from concept to the clinic. , 2010, Current topics in medicinal chemistry.
[78] Gebhard F. X. Schertler,et al. Structure of a β1-adrenergic G-protein-coupled receptor , 2008, Nature.
[79] K. Wreggett,et al. An Intracellular Allosteric Site for a Specific Class of Antagonists of the CC Chemokine G Protein-Coupled Receptors CCR4 and CCR5 , 2008, Molecular Pharmacology.
[80] Yoko Shibata,et al. Thermostabilisation of the neurotensin receptor NTS1 , 2009, Journal of molecular biology.
[81] Oliver P. Ernst,et al. Crystal structure of opsin in its G-protein-interacting conformation , 2008, Nature.
[82] Sebastian Radestock,et al. Homology Model-Based Virtual Screening for GPCR Ligands Using Docking and Target-Biased Scoring , 2008, J. Chem. Inf. Model..
[83] N. Blomberg,et al. An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes. , 2007, Current topics in medicinal chemistry.
[84] C. Tate. Practical considerations of membrane protein instability during purification and crystallisation. , 2010, Methods in molecular biology.
[85] K. Kameyama,et al. Reconstitutively active G protein-coupled receptors purified from baculovirus-infected insect cells. , 1991, The Journal of biological chemistry.
[86] H. Xu,et al. Molecular Recognition of Corticotropin-releasing Factor by Its G-protein-coupled Receptor CRFR1* , 2008, Journal of Biological Chemistry.
[87] Wolfgang Guba,et al. Discovery of the first nonpeptidic, small-molecule, highly selective somatostatin receptor subtype 5 antagonists: a chemogenomics approach. , 2007, Journal of medicinal chemistry.
[88] Vadim Cherezov,et al. A specific cholesterol binding site is established by the 2.8 A structure of the human beta2-adrenergic receptor. , 2008, Structure.
[89] Yoko Shibata,et al. Conformational thermostabilization of the β1-adrenergic receptor in a detergent-resistant form , 2008, Proceedings of the National Academy of Sciences.
[90] Dov Barak,et al. Evaluation of homology modeling of G-protein-coupled receptors in light of the A(2A) adenosine receptor crystallographic structure. , 2009, Journal of medicinal chemistry.
[91] C. Hunte,et al. Specific protein-lipid interactions in membrane proteins. , 2005, Biochemical Society transactions.
[92] C. Koth,et al. Crystal structure of the ectodomain complex of the CGRP receptor, a class-B GPCR, reveals the site of drug antagonism. , 2010, Structure.
[93] Michèle N Schulz,et al. Recent progress in fragment-based lead discovery. , 2009, Current opinion in pharmacology.
[94] P. Portoghese. Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists. , 1989, Trends in pharmacological sciences.
[95] K. Wanner,et al. Methods and Principles in Medicinal Chemistry , 2007 .
[96] Ruben Abagyan,et al. GPCR 3D homology models for ligand screening: Lessons learned from blind predictions of adenosine A2a receptor complex , 2010, Proteins.
[97] Kenneth A Jacobson,et al. Modeling the adenosine receptors: comparison of the binding domains of A2A agonists and antagonists. , 2003, Journal of medicinal chemistry.
[98] M. Caffrey. Crystallizing membrane proteins for structure determination: use of lipidic mesophases. , 2009, Annual review of biophysics.
[99] Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors. , 1997, Molecular endocrinology.
[100] B. Druker,et al. Imatinib as a paradigm of targeted therapies. , 2004, Advances in cancer research.
[101] T. O'Brien,et al. Fragment-based drug discovery. , 2004, Journal of medicinal chemistry.
[102] Ian T. Crosby,et al. Homology Modeling and Docking Evaluation of Aminergic G Protein-Coupled Receptors , 2010, J. Chem. Inf. Model..
[103] P. Goadsby,et al. CGRP and its receptors provide new insights into migraine pathophysiology , 2010, Nature Reviews Neurology.
[104] J. Trujillo-Ferrara,et al. Synthesis, pharmacological and in silico evaluation of 1-(4-di-hydroxy-3,5-dioxa-4-borabicyclo[4.4.0]deca-7,9,11-trien-9-yl)-2-(tert-butylamino)ethanol, a compound designed to act as a beta2 adrenoceptor agonist. , 2009, European journal of medicinal chemistry.
[105] R. Stevens,et al. High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.
[106] Steven O. Smith. Structure and activation of the visual pigment rhodopsin. , 2010, Annual review of biophysics.
[107] M. Congreve,et al. Structure of the adenosine A(2A) receptor in complex with ZM241385 and the xanthines XAC and caffeine. , 2011, Structure.
[108] Marta Filizola,et al. Modern homology modeling of G-protein coupled receptors: which structural template to use? , 2009, Journal of medicinal chemistry.
[109] S. Rasmussen,et al. A monoclonal antibody for G protein–coupled receptor crystallography , 2007, Nature Methods.
[110] R. Abagyan,et al. Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. , 2010, Journal of the American Chemical Society.
[111] J. Popot,et al. Amphipol-assisted in vitro folding of G protein-coupled receptors. , 2009, Biochemistry.
[112] Campbell McInnes,et al. Virtual screening strategies in drug discovery. , 2007, Current opinion in chemical biology.
[113] R. Abagyan,et al. Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists , 2010, Science.
[114] Peter Kolb,et al. Structure-based discovery of β2-adrenergic receptor ligands , 2009, Proceedings of the National Academy of Sciences.
[115] S. Moro,et al. Synthesis and pharmacological characterization of a new series of 5,7-disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazine derivatives as adenosine receptor antagonists: A preliminary inspection of ligand-receptor recognition process. , 2010, Bioorganic & medicinal chemistry.
[116] D. M. Ryan,et al. Rational design of potent sialidase-based inhibitors of influenza virus replication , 1993, Nature.
[117] Markus G Grütter,et al. Opportunities for structure-based design of protease-directed drugs. , 2006, Current opinion in structural biology.
[118] Cheng Zhang,et al. Structure and Function of an Irreversible Agonist-β2 Adrenoceptor complex , 2010, Nature.
[119] Hideo Takahashi,et al. Structural Basis of the Interaction between Chemokine Stromal Cell-derived Factor-1/CXCL12 and Its G-protein-coupled Receptor CXCR4* , 2009, The Journal of Biological Chemistry.
[120] Giuseppe Nano,et al. 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. , 2005, Journal of medicinal chemistry.
[121] Nathan Robertson,et al. The properties of thermostabilised G protein-coupled receptors (StaRs) and their use in drug discovery , 2011, Neuropharmacology.